Back to Business
Business
6 August 2026
Insmed Catapults 30%, Leading A Biotech Rally; But Mirum Takes A Bath
Insmed stock led a biotech rally Thursday, catapulting nearly 40% on solid second-quarter sales for its new lung disease drug.
About this report
Downunder Voices provides an independently written summary and community perspective based on information published by the original source. The original publisher remains responsible for its reporting.
Join our community
Follow Downunder Voices
Join thousands of readers following news and community stories from Australia, New Zealand and the Pacific.
